| 08.00 – 09.00 |
Registration & refreshments
|
| 08.30 – 09.15 |
Breakfast Briefing (optional)
|
| 09.30 – 09.40 |
Opening remarks from the chair
|
| 09.40 – 10.10 |
Keynote & Policy Update: NHS Long Term Plan and the Health & Care Bill – what are the implications for cancer?
- Update on the Galleri trial
- What does the Health & Care Bill mean for cancer care and treatment pathways?
- How integrated care, as a strategy, overcomes the fragmentations in care for people with complex needs
- 62 day cancer waiting target and the two week wait – why do we keep missing these key metrics? If it's not due to Covid, how do we explain it?
- How is the roll out of rapid diagnostic centres progressing?
- Further funding streams for the cancer drugs fund
|
| 10.10 – 10.50 |
Panel: Rising to the challenge of a post pandemic recovery
- Adopting a ‘whole system’ thinking encompassing new treatments for better outcomes, reduce toxicity, and simplifying administration
- What has the Covid pandemic taught us about collaboration? How do we embed this in practice?
- Leveraging advances in telemedicine and remote consultations
- Artificial intelligence and wearables for remote patient monitoring to deliver patient convenience and service efficiencies
- Expanding drive through services and self-administered treatments at home
- How more tolerable treatments (oral and subcutaneous delivery) can increase throughput, ease capacity issues, and improve the patient experience
Panellists:
Speaker to be confirmed, Novartis
Liz Bishop, Chief Executive, Clatterbridge Cancer Centre NHS Foundation Trust
Speaker to be confirmed, Macmillan
|
| 10.50 – 11.20 |
Morning break for refreshments & networking
|
| 11.20 – 12.20 |
Interactive Discussion Groups
Interactive roundtable discussions, each 25 mins duration, so attendees can choose 2 of the following topics:
- Innovative payment models for rare cancers
Moderator to be confirmed, GSK
- Digital technologies to accelerate diagnosis rates and improve system efficiency
- NICE drop in ad Q&A – priorities and strategies for cancer treatments
- Optimising prostate cancer treatment
- What can we learn from the successful roll out of the HPV vaccine?
Moderator to be confirmed, Novartis
- AI technologies to revolutionise cancer care
Moderator to be confirmed, Gilead Sciences
|
| 12.20 – 12.25 |
Transition
|
| 12.25 – 13.05 |
Panel: Tackling inequality in cancer care and treatment
- What is the patient experience? And the relationship between patient and care giver?
- Equality of voice, and the input from frequently ignored communities/patient groups
- Improving access to services, and the ability to self-manage
- How do we allocate resources optimally to address these inequalities in care and treatment?
Moderator: Dr Véronique Walsh, General Manager, UK & Ireland & Vice President, Gilead Sciences
|
| 13.05 – 14.05 |
Lunch
|
| 14.05 – 14.45 |
Panel: Making community diagnostics work
- Building multi-disciplinary teams and nurse-led services
- Supporting the separation of acute and elective diagnostics, providing capacity away from the hospital setting
- Managing the community diagnostics workforce effectively
- Leveraging digital technologies to optimise efficiency and administration
|
| 14.45 – 15.20 |
Panel: How Cancer Alliances are improving care, services and outcomes
- Stakeholders, governance, accountability, and transparency
- Benefits of local and ‘place-based’ planning for cancer care and diagnostics
- How Cancer Alliances are set in the context of Sustainability & Transformation Partnerships (STPs) and their five-year plans
- Impact of Cancer Alliances on reducing inequality of care
Panellists:
David Shackley, Medical Director, Greater Manchester Cancer & Clinical Lead, Manchester Academic Health Science Centre (MAHSC) & Consultant, Salford Royal NHS Foundation Trust
Amanda Pleavin, Managing Director, East of England Cancer Alliance
|
| 15.20 – 15.50 |
Afternoon break for refreshments & networks
|
| 15.50 – 16.20 |
|
How Cheshire & Merseyside Radiology Imaging Network (CAMRIN) is developing Rapid Diagnostics Services (RDS)
- Reviewing cancer imaging across the network
- Optimising pathways and protocols
- Integrating education and training where required
- What results are we seeing so far?
David White, Clinical Lead, Cheshire & Merseyside Imaging Network
|
Advances in lung cancer care and treatment: Stereotactic ablative radiotherapy (SABR)
- Service configuration and service access
- Examining outcomes and the patient experience
Dr Neil Bayman, Medical Director, The Christie NHS Foundation Trust
|
|
| 16.25 – 16.30 |
Transition
|